CompletedNot Applicable

Molecular and Clinical Profile of Von Willebrand Disease in Spain

Spain790 participantsStarted 2017-10-03

Plain-language summary

The present Project is a third phase of the previous PCM-EVW-ES Project (Batlle et al. Thromb \& Haemost 2015) with the aim of its extension, further analysis with an innovation development in the field of von Willebrand disease (VWD) based in the newer recently available methodologies. The aim of this project is to help the physician in a more uniform characterization and therapy of VWD in clinical practice, at an international level. A reduction of the expenses in the diagnosis process by using the new methodologies is pursued.

Who can participate

Age range2 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. VWF ≤ 30 IU/d, in 2 or more occasions.
✓. Presence of multimeric abnormalities.
✓. If isolated FVIII deficiency demonstration of decreased FVIII binding.
✓. Presence of some VWF mutation.
✓. ↑ RIPA at low concentrations of ristocetin.

Exclusion criteria

✕. Presence of any data suggesting AVWS.
✕. Absence of a signed patient informed consent

What they're measuring

Central diagnosis of 400 new VWD Spanish patients

Timeframe: January 2019

Trial details

NCT IDNCT02869074

SponsorSpanish Society of Thrombosis and Haemostasis

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-09-25

View on ClinicalTrials.gov More Von Willebrand Disease trials